Allena Pharmaceuticals Inc. (ALNA)
$0.01
$0.00
(-10.40%)
As on 09-Nov-2022 09:30EDT
Market cap
$9 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-43 Mln
-
ROE
-5.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
122,083,000
7 Years Aggregate
CFO
$-206.94 Mln
EBITDA
$-204.54 Mln
Net Profit
$-209.08 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Allena Pharmaceuticals (ALNA)
| -98.1 | -32.1 | -91.8 | -98.9 | -82.2 | -75.0 | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|
|
Allena Pharmaceuticals (ALNA)
| -53.7 | -53.1 | -49.9 | -45.6 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Allena Pharmaceuticals (ALNA)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is... ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. Read more
-
Co-Founder & Chairman
Dr. Alexey L. Margolin Ph.D.
-
Co-Founder & Chairman
Dr. Alexey L. Margolin Ph.D.
-
Headquarters
Newton, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Allena Pharmaceuticals (ALNA)
What is the current share price of Allena Pharmaceuticals Inc (ALNA) Today?
The share price of Allena Pharmaceuticals Inc (ALNA) is $0.01 (NASDAQ) as of 09-Nov-2022 09:30 EDT. Allena Pharmaceuticals Inc (ALNA) has given a return of -82.24% in the last 3 years.
What is the current PB & PE ratio of Allena Pharmaceuticals Inc (ALNA)?
Since, TTM earnings of Allena Pharmaceuticals Inc (ALNA) is negative, P/E ratio is not available.
The P/B ratio of Allena Pharmaceuticals Inc (ALNA) is 1.86 times as on 09-Nov-2022, a 55 discount to its peers’ median range of 4.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of Allena Pharmaceuticals Inc (ALNA)?
The 52-week high and low of Allena Pharmaceuticals Inc (ALNA) are Rs -- and Rs -- as of 20-Jun-2026.
What is the market cap of Allena Pharmaceuticals Inc (ALNA)?
Allena Pharmaceuticals Inc (ALNA) has a market capitalisation of $ 9 Mln as on 09-Nov-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Allena Pharmaceuticals Inc (ALNA)?
Before investing in Allena Pharmaceuticals Inc (ALNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.